Monte Rosa Therapeutics, Inc. reported a substantial increase in collaboration revenue for Q1 2025, leading to a net income of $46.885 million, a significant improvement from a net loss in the prior year. The company's operating expenses also increased, primarily due to higher research and development costs.

Monte Rosa Therapeutics delivered a strong Q4 2024, achieving $60.6 million in collaboration revenue and net income of $13.4 million. The company reported significant progress in its pipeline, particularly with MRT-6160 and MRT-2359, and ended the quarter with a robust cash position to support operations into 2028.